Main Belt Comets as Clues to the Distribution of Water in the Early Solar System

n/

Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection

Background: Chronic hepatitis B virus (HBV) infection and dietary aflatoxin B1 (AFB1) exposure are etiological factors for hepatocellular carcinoma (HCC) in countries with hot, humid climates. HCC often harbors a TP53 (tumor protein p53) mutation at codon 249 (R249S). In chronic carriers, 1762T/1764A mutations in the HBV X gene are associated with increased HCC risk. Both mutations have been detected in circulating cell-free DNA (CFDNA) from asymptomatic HBV carriers

Zinc deficiency and neurodevelopment: the case of neurons

Zinc is essential for normal brain development. Gestational severe zinc deficiency can lead to overt fetal brain malformations. Although not teratogenic, suboptimal zinc nutrition during gestation can have long-term effects on the offspring's nervous system. This article will review current knowledge on the role of zinc in modulating neurogenesis and neuronal apoptosis as well as the proposed underlying mechanisms. A decrease in neuronal zinc causes cell cycle arrest, which in part involves a deregulation of select signals (ERK1/2, p53, and NF-κB). Zinc deficiency also induces apoptotic neuronal death through the intrinsic (mitochondrial) pathway, which can be triggered by the activation of the zinc-regulated enzyme caspase-3, and as a consequence of abnormal regulation of prosurvival signals (ERK1/2 and NF-κB). Alterations in the finely tuned processes of neurogenesis, neuronal migration, differentiation, and apoptosis, which involve the developmental shaping of the nervous system, could have a long-term impact on brain health. Zinc deficiency during gestation, even at the marginal levels observed in human populations, could increase the risk for behavioral/neurological disorders in infancy, adolescence, and adulthood.Fil: Adamo, Ana María. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Oteiza, Patricia Isabel. University of California at Davis; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Author manuscript, published in "VaMoS'13- Seventh International Workshop on Variability Modelling of Software-Intensive Systems (2013)" Support for Reverse Engineering and Maintaining Feature Models

Feature Models (FMs) are a popular formalism for modelling and reasoning about commonality and variability of a system. In essence, FMs aim to define a set of valid combinations of features, also called configurations. In this paper, we tackle the problem of synthesising an FM from a set of configurations. The main challenge is that numerous candidate FMs can be extracted from the same input configurations, yet only a few of them are meaningful and maintainable. We first characterise the different meanings of FMs and identify the key properties allowing to discriminate between them. We then develop a generic synthesis procedure capable of restituting the intended meanings of FMs based on inferred or user-specified knowledge. Using tool support, we show how the integration of knowledge into FM synthesis can be realized in different practical application scenarios that involve reverse engineering and maintaining FMs. 1

Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)

Abstract Background Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic lesions in the absence of any detectable primary tumor. Although they often adopt an aggressive clinical pattern, their basic biology remains poorly understood. Laboratory research on their biology have been hampered so far by the absence of cell lines representative of CUPs. Methods We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells. Whenever possible, malignant xenografted or cultured cells were characterized by microsatellite genotyping, immunohistology, electron microscopy, multifish chromosome analysis and search of TP 53 gene mutations. Results Successful xenografts were achieved in 2 cases out of 4. One of them (Capi1) was lost after 3 passages whereas the other one (Capi3) has been adapted to in vitro culture and is currently available to the scientific community with reliable identification based on microsatellite genotyping. Both Capi1 and Capi3 have histological characteristics of adenocarcinomas and display intense expression of EMA, CEA and cytokeratin 7. Multifish chromosome analysis demonstrated a translocation involving chromosomes 4 and 21 in both specimens. Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens. Finally, intense membrane expression of c-kit was recorded in Capi3. Conclusion Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP clinical specimens. The hypothesis of a preferential association of CUPs with TP 53 mutations of codon 181 deserves further investigations. The Capi3 cell line will be a useful tool for assessment of novel c-kit inhibitors.</p

Utilisation clinique et évolution des biomarqueurs circulants à l’ère de l’oncologie personnalisée : des marqueurs protéiques aux scores clinicobiologiques

International audienceTechnological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. These new tools have profoundly changed therapeutic management in oncology, with increasingly precise molecular characterization of tumors leading to increasingly personalized therapeutic targeting. Detection of circulating tumor cells and/or circulating tumor DNA in blood samples -so-called 'liquid biopsies'- can now provide a genetic snapshot of the patient's tumor through an alternative and less invasive procedure than biopsy of the tumor tissue itself. This procedure for characterizing and monitoring the disease in real time facilitates the search for possible relapses, the emergence of resistance, or emergence of a new therapeutic target. In the long term, it might also provide a means of early detection of cancer. These new approaches require the treatment of ever-increasing amounts of clinical data, notably, with the goal of calculating composite clinical-biological predictive scores. The use of artificial intelligence will be unavoidable in this domain, but it raises ethical questions and implications for the health-care system that will have to be addressed.Les progrès technologiques, en particulier le développement du séquençage à haut débit, ont conduit à l’émergence d’une nouvelle génération de biomarqueurs tumoraux moléculaires. Ces nouveaux outils ont profondément modifié la prise en charge thérapeutique en oncologie avec une caractérisation moléculaire de plus en plus précise des tumeurs amenant à un ciblage thérapeutique personnalisé. La détection des cellules tumorales circulantes et/ou de l’ADN tumoral circulant dans des prélèvements sanguins, encore appelés « biopsies liquides », peut désormais fournir un instantané du profil génétique de la tumeur du patient grâce à une procédure alternative et moins invasive qu’une biopsie du tissu tumoral lui-même. Cette méthode de caractérisation moléculaire et de suivi de la maladie en temps réel facilite la recherche d’éventuelles rechutes, de l’émergence de résistances ou d’une nouvelle cible thérapeutique. À long terme, les biopsies liquides pourraient également fournir un moyen de détection précoce du cancer. Ces nouvelles approches nécessitent le traitement d’une quantité, toujours croissante, de données, en particulier cliniques, notamment dans l’optique d’élaborer des scores clinico-biologiques composites. L’utilisation de l’intelligence artificielle est un outil d’avenir dans ce domaine, mais elle soulève des questions éthiques et des implications pour l’organisation du système de santé qui devront être abordées

24 colour multifish karyotype showing the complexity of the genomic rearrangements with rearranged chromosomes in most pairs and several unidentified marker chromosomes (bottom left)

<p><b>Copyright information:</b></p><p>Taken from "Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)"</p><p>http://www.biomedcentral.com/1471-2407/7/225</p><p>BMC Cancer 2007;7():225-225.</p><p>Published online 18 Dec 2007</p><p>PMCID:PMC2241840.</p><p></p> Of particular interest are the translocation of chromosome 21 (in green) to the distal chromosome 4 (in grey) and the loss of chromosomes 9. In this cell, there were 2 der(3)t(3, 15) instead of one in most other cells which were analyzed

Microsatellite tracking assay linking DNA from patient peripheral blood mononuclear cells (PBMC), tumor surgical specimen (Surg

<p><b>Copyright information:</b></p><p>Taken from "Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)"</p><p>http://www.biomedcentral.com/1471-2407/7/225</p><p>BMC Cancer 2007;7():225-225.</p><p>Published online 18 Dec 2007</p><p>PMCID:PMC2241840.</p><p></p> Spec.) and xenograft to the Capi3 cell line